Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)
Status:
Terminated
Trial end date:
2010-01-20
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the
efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms
(LUTS) secondary to benign prostatic hyperplasia (BPH) in men as assessed by the
International Prostate Symptom Score (IPSS) at Week 14.